Benzinga | Jul 1, 2021 08:18AM EDT

Summit Therapeutics Highlights Presentation Of Research Updates At Annual European Congress of Clinical Microbiology & Infectious Diseases Conference Jul. 9-12

Summit Therapeutics Inc. (NASDAQ:SMMT) (the "Company") today announced that members of our scientific team will present breakthrough research updates at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will be held virtually July 9 -- 12. Our three posters to be presented are as follows, one of which was designated as a Top Rated ePoster by the ECCMID conference:

* ECCMID Top Rated ePoster: Metagenomic Analysis of the Impact of the Precision Antibiotic Ridinilazole, Compared to Vancomycin, on the Gut Resistome in a Phase II Study

* Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study

* Identification of the Mechanism of Action for Ridinilazole, a Phase III Antibiotic for Treatment of Clostridioides difficile

Ridinilazole is our investigational drug currently in Phase III Ri-CoDIFy clinical trials with the goal of use as first-line therapy to treat initial infection and reduce recurrence of Clostridioides difficile infection.

Clostridioides difficile, or C. difficile, infection (CDI) is highly infectious disease that affects over 500,000 patients in the United States each year with approximately 25% of initial cases resulting in recurrent infections. Along with emotional and physical suffering, symptoms include inflammation of the colon, severe watery diarrhea, painful abdominal cramping, nausea, fever, dehydration, and in more severe cases, bowel perforation and sepsis. CDI is responsible for an estimated 20,000 to 30,000 deaths in the US each year with annual acute care costs estimated to be $5.4 billion. Dysbiosis (dysfunction) of the gut microbiota is a major risk factor for initial instances of and recurrence of the disease.

Upon the completion of the conference, each poster will be available within the "Scientific Literature & Publications" section of our website: https://www.summittxinc.com/publications/.